

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Contents lists available at ScienceDirect

Medical Hypotheses

journal homepage: www.elsevier.com/locate/mehy



Calcitonin gene-related peptide: A biomarker for stroke in SARS-CoV-2 infection?

ARTICLE INFO	A B S T R A C T
Keywords COVID-19 CGRP Ischemic stroke CBF	COVID-19 infection was mainly associated with respiratory symptoms, but lately, ischemic stroke (IS) has been reported in several cases. The incidence of IS in SARS-CoV-2 infection is increasing, and its mechanism is still not fully understood. Calcitonin gene-related peptide (CGRP) -the abundantly expressed protein in the peripheral and central nervous system- showed low expression in SARS-CoV-2 patients. This peptide is strongly implicated in regulating cerebral blood flow (CBF) and improving neurological deficits after cerebral arterial occlusion. We assume that a possible interplay between the low circulating levels of CGRP may affect CBF, thus worsening the symptoms of IS in SARS-CoV-2 patients.

Introduction

The association of Ischemic stroke (IS) and SARS-CoV-2 infection was reported with an occurrence of up to 4.9% during initial hospitalization [1]. However, the exact mechanism underlying these lesions remains unclear.

Calcitonin gene-related peptide (CGRP) is a vasoactive peptide released from sensory nerves and involved in attenuating cerebral ischemia, CGRP regulates the subfamilies of mitogen-activated protein kinase [2] and promote cell proliferation through the Wnt/ β -catenin pathway as seen in the figure [3]. Therefore, CGPR can improve motor and sensitive functions after middle cerebral artery occlusion, as reported in an *in vivo* study [3]. Furthermore, besides its neuroprotective effects, CGRP has an anti-inflammatory role by reducing interleukin-2 production [4].

Recently a published case report by Aradi et al. 2019 indicated an association between CGRP antagonists and IS in young women; therefore, the decreased levels of CGRP might suppress its protective vasodilatory effect in cerebral arteries [5].

Interestingly, autopsies of SARS-CoV-2 infection cases revealed that nerve tissues are damaged [6]. In addition, Ochoa-Callejero et al. 2021 [4] observed that serum CGRP levels were significantly lower in 57 SARS-CoV-2 patients. Consequently, low CGRP levels might be correlated with cerebral vasospasm and ischemic lung lesions.

All the presented data herein were relevant to the conclusion that the low CGRP levels in SARS-CoV-2 infections might be a culprit in the ischemic process and worsening the brain arterial occlusion, thus leading to IS.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Abbreviations: CGRP, Calcitonin gene-related peptide; CBF, Cerebral blood flow.

https://doi.org/10.1016/j.mehy.2022.110807

Received 29 November 2021; Received in revised form 11 January 2022; Accepted 10 February 2022 Available online 23 February 2022 0306-9877/© 2022 Elsevier Ltd. All rights reserved.

Acknowledgements

The authors are thankful for biorender.com for creating the figures and graphical abstract with license number (YJ23EWE1KS).

References

- Qureshi AI, Baskett WI, Huang W, Shyu D, Myers D, Raju M, et al. Acute ischemic stroke and COVID-19. Stroke 2021;52(3):905–12. https://doi.org/10.1161/ STROKEAHA 120.031786
- [2] Yang S, Yuan Y, Jiao S, Luo Q, Yu J. Calcitonin gene-related peptide protects rats from cerebral ischemia/reperfusion injury via a mechanism of action in the MAPK pathway. Biomed Rep 2016;4:699–703. https://doi.org/10.3892/br.2016.658.
- [3] Du Z, Zhang H, Chen Q, Gao Y, Sun B. Intranasal calcitonin gene-related peptide protects against focal cerebral ischemic injury in rats through the Wnt/β-catenin pathway. Med Sci Monit 2018;24:8860–9.
- [4] Ochoa-Callejero L, García-Sanmartín J, Villoslada-Blanco P, Íniguez M, Pérez-Matute P, Pujadas E, et al. Circulating levels of calcitonin gene-related peptide are lower in COVID-19 patients. J Endocr Soc 2021;5(3). https://doi.org/10.1210/ jendso/bvaa199.
- [5] Aradi S, Kaiser E, Cucchiara B. Ischemic stroke associated with calcitonin generelated peptide inhibitor therapy for migraine: a case report. J Stroke Cerebrovas Dis 2019;28(10):104286. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.07.002.
- [6] Satarker S, Nampoothiri M. Involvement of the nervous system in COVID-19: The bell should toll in the brain. Life Sci 2020;262:118568. https://doi.org/10.1016/j. lfs.2020.118568.

Yassamine Ouerdane^a, Yahia Khlidj^b, Mohamed S. Attia^{c,*}, Rafik Korissi^b

^a Faculty of Medicine, Saad Dahlab University, Blida, Algeria

^b Faculty of Medicine, University of Algiers Benyoucef Benkhedda, Algiers, Algeria

^c Department of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt

> ^{*} Corresponding author. *E-mail address:* msalahatia@zu.edu.eg (M.S. Attia).





